NewAmsterdam Pharma Ownership | Who Owns NewAmsterdam Pharma?


OverviewForecastRevenueFinancialsChart

NewAmsterdam Pharma Ownership Summary


NewAmsterdam Pharma is owned by 10.30% institutional investors, 0.47% insiders, and 89.24% retail investors. Frazier life sciences management is the largest institutional shareholder, holding 14.84% of NAMS shares. American Funds SMALLCAP World A is the top mutual fund, with 7.48% of its assets in NewAmsterdam Pharma shares.

NAMS Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockNewAmsterdam Pharma10.30%0.47%89.24%
SectorHealthcare Stocks 231.98%10.74%-142.72%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Frazier life sciences management16.70M14.84%$475.00M
Bain capital life sciences investors10.72M9.53%$304.85M
Ra capital management10.14M9.01%$288.35M
Capital world investors9.98M8.39%$350.24M
Fcpm iii services b.v.9.21M8.19%$262.00M
Viking global investors lp6.48M5.76%$184.16M
Fmr5.54M4.92%$157.42M
Deerfield management company, l.p. (series c)4.27M3.79%$121.34M
Wellington management group llp4.02M3.57%$114.33M
Jennison associates3.49M2.93%$122.40M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Fcpm iii services b.v.9.21M52.36%$262.00M
Bain capital life sciences investors10.72M20.23%$304.85M
Frazier life sciences management16.70M14.23%$475.00M
Medicxi ventures management (jersey)2.87M12.06%$100.66M
Cormorant asset management, lp2.17M4.27%$61.86M
Ra capital management10.14M3.55%$288.35M
First turn management716.97K3.06%$20.39M
Decheng capital592.06K2.79%$20.77M
Healthinvest partners ab197.04K2.21%$6.91M
Deerfield management company, l.p. (series c)4.27M1.85%$121.34M

Top Buyers

HolderShares% AssetsChange
Fmr5.54M0.01%3.63M
Duquesne family office1.92M1.35%1.09M
Goldman sachs group1.73M0.01%845.11K
Wellington management group llp4.02M0.02%697.13K
Ensign peak advisors549.51K0.03%549.51K

Top Sellers

HolderShares% AssetsChange
Fcpm iii services b.v.9.21M52.36%-1.42M
Morgan stanley532.80K0.00%-964.68K
Deerfield management company, l.p. (series c)4.27M1.85%-849.26K
Siren---765.71K
Woodline partners lp1.16M0.15%-739.33K

New Positions

HolderShares% AssetsChangeValue
Ensign peak advisors549.51K0.03%549.51K$19.28M
Jane street group421.49K0.00%421.49K$14.79M
Lord, abbett200.64K0.02%200.64K$7.04M
Axa investment managers196.78K0.02%196.78K$5.60M
Moody aldrich partners143.55K0.94%143.55K$5.04M

Sold Out

HolderChange
Principal securities-13.00
Coldstream capital management-24.00
Clearstead advisors-88.00
Assetmark-96.00
Advisor group-142.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202555-62.07%12,251,519-89.84%100.09%32-58.44%10-72.97%
Sep 30, 202543-66.67%10,963,801-90.21%90.10%20-75.61%10-62.96%
Jun 30, 20251353.05%116,309,19516.74%1031.40%8511.84%28-9.68%
Mar 31, 2025135-3.57%111,187,22812.82%950.89%78-11.36%336.45%
Dec 31, 202433-67.96%21,547,862-71.71%220.35%19-71.64%8-52.94%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
American Funds SMALLCAP World A8.60M7.48%-
Vanguard Health Care Inv3.67M3.19%823.72K
Polar Capital Biotech S Inc2.63M2.28%-
Capital Group Global Equity Canada F2.52M2.19%-
Fidelity Contrafund986.17K0.86%-
PGIM Jennison Small Company A966.54K0.84%-
Jennison SMid Cap Core Equity966.54K0.84%-119.37K
AB Small Cap Growth A686.06K0.61%32.56K
Pictet-Global Megatrend Sel I USD682.29K0.61%10.43K
Candriam Eqs L Biotech C USD Cap684.30K0.60%13.07K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 02, 2026Davidson Michael H. Chief Executive OfficerSell$14.75M
Feb 25, 2026Davidson Michael H. Chief Executive OfficerSell$1.63M
Feb 26, 2026Davidson Michael H. Chief Executive OfficerSell$5.56M
Feb 24, 2026Davidson Michael H. Chief Executive OfficerSell$2.22M
Feb 25, 2026Davidson Michael H. Chief Executive OfficerSell$375.28K

Insider Transactions Trends


DateBuySell
2026 Q1-25
2025 Q4-3
2025 Q3310
2025 Q235
2025 Q1217

NAMS Ownership FAQ


Who Owns NewAmsterdam Pharma?

NewAmsterdam Pharma shareholders are primarily institutional investors at 10.30%, followed by 0.47% insiders and 89.23% retail investors. The average institutional ownership in NewAmsterdam Pharma's industry, Biotech Stocks , is 381.47%, which NewAmsterdam Pharma falls below.

Who owns the most shares of NewAmsterdam Pharma?

NewAmsterdam Pharma’s largest shareholders are Frazier life sciences management (16.7M shares, 14.84%), Bain capital life sciences investors (10.72M shares, 9.53%), and Ra capital management (10.14M shares, 9.01%). Together, they hold 33.38% of NewAmsterdam Pharma’s total shares outstanding.

Does Blackrock own NewAmsterdam Pharma?

BlackRock is not among the top 10 institutional shareholders of NewAmsterdam Pharma.

Who is NewAmsterdam Pharma’s biggest shareholder by percentage of total assets invested?

Fcpm iii services b.v is NewAmsterdam Pharma’s biggest shareholder by percentage of total assets invested, with 52.36% of its assets in 9.21M NewAmsterdam Pharma shares, valued at 262M$.

Who is the top mutual fund holder of NewAmsterdam Pharma shares?

American Funds SMALLCAP World A is the top mutual fund holder of NewAmsterdam Pharma shares, with 7.48% of its total shares outstanding invested in 8.6M NewAmsterdam Pharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools